Aetna modified CPB 0961 governing givosiran (Givlaari) coverage for acute hepatic porphyria, effective January 11, 2026. Here's what billing teams need to do.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0961 for givosiran (Givlaari), a subcutaneous injectable billed under HCPCS J0223. This coverage policy governs medical necessity criteria for acute hepatic porphyria (AHP) treatment across commercial plan designs. If your practice or specialty pharmacy bills J0223 or administers givosiran under CPT 96372, this update directly affects your prior authorization workflow and claim submission process.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Givosiran (Givlaari) — CPB 0961 |
| Policy Code | CPB 0961 |
| Change Type | Modified |
| Effective Date | January 11, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, Internal Medicine, Specialty Pharmacy, Infusion/Injection Centers |
| Key Action | Confirm all givosiran (J0223) prior authorizations meet updated medical necessity criteria before submitting claims after January 11, 2026 |
Aetna Givosiran Coverage Criteria and Medical Necessity Requirements 2026
The CPB 0961 Aetna coverage policy sets three hard requirements for initial approval. Your patient must meet all three — not just one or two.
Criterion one: Age. The member must be 18 years of age or older. There is no pathway for pediatric coverage under this policy.
Criterion two: Active disease burden. The member must be either actively symptomatic — meaning porphyria attacks that required hospitalization, urgent healthcare visits, or intravenous hemin administration — or have experienced four or more porphyria attacks per year. This is a clinical threshold, not a checkbox. Your documentation must show frequency or severity.
Criterion three: Lab confirmation. The member must have an elevated urine porphobilinogen (PBG) or an elevated porphyrin level from plasma or fecal testing. This ties directly to two CPT codes in the policy: CPT 84110 (urine PBG, quantitative) and CPT 84126 (fecal porphyrins, quantitative). These lab results need to be in your prior auth submission. Missing lab documentation is a fast path to claim denial.
Precertification is mandatory for all Aetna participating providers and members on applicable plan designs. Call 866-752-7021 or fax 888-267-3277 to start the process. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal.
This policy also falls under Aetna's GCIT® (Gene-based, Cellular & Other Innovative Therapies) program. That means the Aetna GCIT team handles review — not standard prior auth reviewers. Expect a more detailed clinical review process than you'd see for routine specialty drugs.
Givosiran billing also triggers Aetna's Site of Care Utilization Management policy for specialty drug infusions. Where the drug is administered affects reimbursement. Confirm your site of service is compliant before the first claim goes out.
Aetna Givosiran Exclusions and Non-Covered Indications
The policy is explicit: Aetna considers all indications other than AHP experimental, investigational, or unproven.
There are no off-label pathways buried in the policy. No compassionate use criteria. No exceptions for related porphyria subtypes unless they meet the ICD-10 criteria listed below. If the diagnosis code doesn't map to E80.20, E80.21, or E80.29, your claim won't pass.
This matters because AHP is a spectrum. Clinicians sometimes document related conditions in ways that don't clearly map to these three codes. Work with your clinical team to confirm the diagnosis coding before prior auth submission. A vague or incorrect ICD-10 on the auth request means a denial before the drug is even dispensed.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Acute hepatic porphyria (AHP) — active symptoms (hospitalization, urgent visit, or IV hemin) | Covered | J0223, E80.20, E80.21, E80.29 | All three criteria must be met; prior auth required |
| Acute hepatic porphyria (AHP) — 4+ attacks per year (without current active symptoms) | Covered | J0223, E80.20, E80.21, E80.29 | Attack frequency must be documented; prior auth required |
| Continuation of therapy — member showing benefit (reduced hospitalizations, urgent visits, or IV hemin) | Covered | J0223, 96372 | Benefit must be documented at renewal |
| All other indications (off-label use) | Not Covered — Experimental/Investigational | — | No exceptions listed in CPB 0961 |
Aetna Givosiran Billing Guidelines and Action Items 2026
The effective date is January 11, 2026. If you bill J0223 or administer givosiran, here's what to do now.
| # | Action Item |
|---|---|
| 1 | Audit your active givosiran prior authorizations. Pull every open auth for J0223. Confirm each one has documentation covering all three criteria: age verification, attack frequency or active symptom documentation, and lab results for CPT 84110 or CPT 84126. Any auth missing lab evidence is a claim denial waiting to happen. |
| 2 | Update your prior auth intake forms before January 11, 2026. Your intake process should prompt clinical staff to collect urine PBG results (84110) or plasma/fecal porphyrin results (84126) at the time of prior auth initiation. Don't chase labs after the fact. |
| 3 | Confirm site of care compliance before billing CPT 96372. Aetna's Site of Care UM policy applies here. If your practice administers givosiran via subcutaneous injection (CPT 96372), verify that your site of service is the most appropriate and cost-effective setting per Aetna's infusion site of care policy. Billing from a non-preferred site of care risks a site-of-service denial even when the drug auth is approved. |
| 4 | Route all prior auth requests through the GCIT review channel. Aetna flags givosiran as a GCIT product. That means the standard commercial prior auth pathway may not be sufficient. Call 866-752-7021 or fax the SMN to 888-267-3277, and make sure your submission reaches the GCIT team. An auth processed through the wrong channel can delay approval or result in a denial. |
| 5 | Document continuation criteria at every renewal. For patients already on givosiran, Aetna requires evidence of clinical benefit at renewal. Specifically: reduction in porphyria attacks that required hospitalizations, urgent healthcare visits, or IV hemin administration. Build this into your renewal workflow now. "Patient tolerating therapy" is not sufficient. You need quantified attack frequency data before and after treatment start. |
| 6 | Confirm ICD-10 coding aligns with covered diagnoses. Your claims must carry E80.20, E80.21, or E80.29. If your documentation reflects a porphyria variant that doesn't clearly map to these codes, flag it for your compliance officer or billing consultant before submitting. A mismatched diagnosis code will trigger a denial and potentially a recoupment if discovered on audit. |
| 7 | Talk to your compliance officer if you're unsure how the GCIT designation affects your billing workflow. The GCIT program adds a layer of review that standard specialty billing teams may not have encountered. If your team hasn't billed a GCIT product before, get ahead of it before the effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Givosiran (Givlaari) Under CPB 0961
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J0223 | HCPCS | Injection, givosiran, 0.5 mg |
J0223 is the primary billing code for givosiran. Unit billing matters here — J0223 is priced per 0.5 mg. Confirm your dose against the approved quantity on the auth before submitting. Dose mismatches between the auth and the claim are a common source of denials on high-cost specialty injectables.
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| E80.20 | Unspecified porphyria |
| E80.21 | Acute intermittent (hepatic) porphyria |
| E80.29 | Other porphyria |
E80.21 is the most clinically specific code for the condition this drug treats. E80.20 and E80.29 are acceptable but carry more risk in audit situations. Use the most specific code your documentation supports.
Get the Full Picture for CPT 96372
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.